

## Navin Molecular to invest \$35 M for expanding manufacturing capabilities

03 July 2024 | News

**New 9,000-square-meter facility will nearly double the site's overall capacity to 420 cubic meters**



Navin Molecular, a Madhya Pradesh-headquartered Contract Development and Manufacturing Organisation (CDMO), has announced a significant investment of Rs 288 crore (approximately \$35 million) to expand its GMP manufacturing plant in Dewas.

The new 9,000-square-meter facility will nearly double the site's overall capacity to 420 cubic meters, supporting existing commercial-scale projects and meeting future demand as the company continues to grow its global customer base.

The multi-purpose facility will add 200 cubic meters of manufacturing capacity, incorporating various vessel types including stainless steel, glass-lined, Hastelloy, and Inconel. It will handle a wide range of chemistries, including hazardous processes such as direct fluorination, cyanation, azide chemistry, cryogenic reactions, and high-pressure hydrogenation. The plant will feature a high level of automated control, including a distributed control system (DCS), enhancing efficiency and minimizing risks to employees and the environment.

The expansion will also boost the size and capacity of the site's existing 21 CFR-compliant QC laboratory for in-process testing and final product release. A new process safety laboratory and a dedicated zero liquid discharge (ZLD) effluent treatment plant will be constructed. The facility will adhere to India's optimum green building concepts, leveraging modern technologies in materials, equipment, and design, including renewable energy generation and solvent containment. A ground-breaking ceremony was held in April 2024, and the project is expected to be completed by the end of 2025, creating up to 100 new jobs.

Navin Molecular, launched in 2023 as the CDMO division of Navin Fluorine, supports global pharmaceutical innovators. Its 47-acre state-of-the-art site in Dewas offers process research and development through to commercial manufacturing of a wide range of regulatory starting materials and API intermediates.